

3-7 **2022 ASCO**  
June ANNUAL MEETING



## The French Cancer Cooperative network (GCO) at ASCO & EHA 2022



The GCO network is a French network of ten cooperative groups conducting cancer clinical and translational research in France and in other countries. Most of these groups are organ specific (e.g., lung, digestive, gynecologic, lymphoma, leukemia, myeloma, head and neck, and brain cancers...). They are all not-for-profit organizations (regulated by the French law of 1901) and have been accredited “French cooperative intergroup of international dimension in the field of cancer” by the French National Cancer Institute (INCa).

**You will find below the (non-exhaustive) list of abstracts selected at ASCO and EHA 2022 on clinical and translational research led by seven members of the network (ARCAGY-GINECO, FFCD, GERCOR, IFCT, IFM, LYSA-LYSARC & SFCE : 9 oral presentations, 10 poster discussions, and 19 poster sessions**

COLORECTAL AND NON COLORECTAL CANCERS.....	2
GYNECOLOGIC CANCERS .....	3
LUNG CANCERS.....	4
PEDIATRIC CANCERS.....	6
MALIGNANT HEMOPATHIES.....	6

## COLORECTAL AND NON-COLORECTAL CANCERS

FFCD : Fédération Francophone de Cancérologie Thoracique  
*Francophone Federation of Digestive Tract Cancerology*

### POSTER SESSION - ASCO 2022

The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.

David Tougeron

[Abstract](#)

### POSTER SESSION - ASCO 2022

PRODIGE 25 - FOLFA : Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers. Results of a randomized FOLFA phase II trial

Jean-Louis Legoux

[Abstract](#)

GERCOR : Groupe Coopérateur Multidisciplinaire en Oncologie  
*Multidisciplinary Oncology Cooperative Group*

### ORAL ABSTRACT SESSION - ASCO 2022

STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Wild-Type KRAS/NRAS/BRAF Metastatic Colorectal Cancer. A GERCOR C12-2 PRODIGE 39 Randomized Open-label Phase III study.

Benoist Chibaudel

[Abstract](#)

### ORAL ABSTRACT SESSION - ASCO 2022

Adapted Physical Activity in patients (Pts) with advanced Pancreatic Cancer (APACaP): results from a prospective national randomized GERCOR trial.

Cindy Neuzillet

[Abstract](#)

### ORAL ABSTRACT SESSION - ASCO 2022

Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma. A SCARCE-PRODIGE 60 randomized phase II study.

Stefano Kim

[Abstract](#)

#### **POSTER SESSION - ASCO 2022**

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.

Thierry Andre

[Abstract](#)

#### **POSTER SESSION - ASCO 2022**

A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.

Marc Hilmi

[Abstract](#)

#### **POSTER SESSION - ASCO 2022**

Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study.

Matthieu Delaye

[Abstract](#)

#### **POSTER SESSION - ASCO 2022**

One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.

Romain Cohen

[Abstract](#)

## **GYNECOLOGIC CANCERS**

**ARCAGY - Association de Recherche sur les Cancers dont GYNécologiques**

**GINECO - Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens et du sein**

*Cooperative Gynecological Cancer Research Group*

#### **POSTER DISCUSSION SESSION - ASCO 2022**

Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial.

Jalid Sehouli

[Abstract](#)

#### **POSTER SESSION - ASCO 2022**

Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study.

Benoit You

[Abstract](#)

**POSTER SESSION - ASCO 2022**

Immune tumor microenvironment (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: Novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO/GINEGEPS study.

Felix Blanc-Durand

[Abstract](#)

**POSTER SESSION - ASCO 2022**

Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Final complete resection and pathological response rates.

Alexandra Leary

[Abstract](#)

**POSTER SESSION - ASCO 2022**

OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts.

PAOLA-1 (QoI)

Jean-Emmanuel Kurtz

[Abstract](#)

**POSTER SESSION - ASCO 2022**

Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644).

Jean Emmanuel Kurtz

[Abstract](#)

**POSTER SESSION - ASCO 2022**

Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial.

Florence Joly

[Abstract](#)

**POSTER SESSION - ASCO 2022**

Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.

Sana Intidhar Labidi-Galy

[Abstract](#)

## TRIALS IN PROGRESS – POSTER SESSION - ASCO 2022

TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab versus best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.

Alexandra Leary

[Abstract](#)

ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.

Nicoletta Colombo

[Abstract](#)

ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

Susana N. Banerjee

[Abstract](#)

AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).

Philipp Harter

[Abstract](#)

## LUNG CANCERS

### IFCT : Intergroupe Francophone de Cancérologie Thoracique

#### POSTER SESSION - ASCO 2022

Efficacy of dabrafenib-trametinib combination in BRAF V600E-mutated metastatic non-small cell lung cancer: Results of the IFCT-2004 BLaDE cohort.

Aurélie Swalduz

[Abstract](#)

#### POSTER SESSION - ASCO 2022

The Lung ART adjuvant radiotherapy phase 3 randomized trial: Impact of quality of resection in stage IIIAN2 patients.

Pascal Thomas

[Abstract](#)

#### TRIAL IN PROGRESS - POSTER SESSION - ASCO 2022

A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non-small cell lung cancer (IFCT-2101 MASTERPROTOCOL ALK).

Michael Duruisseaux

[Abstract](#)

## PEDIATRIC CANCERS

**SFCE : Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent**

*French Society for the Fight against Cancer and Leukemia in Children and Adolescents*

### ORAL ABSTRACT SESSION - ASCO 2022

Securing access to innovative anticancer therapies for children, adolescents, and young adults outside clinical trials: The SACHA study of the French Society of Pediatric Oncology (SFCE).

Pablo Berlanga

[Abstract](#)

## HEMOPATHIES MALIGNES

**LYSA : The LYmphoma Study Association**

### POSTER DISCUSSION SESSION – ASCO 2022

Sub- Cutaneous Rituximab Induction Followed by Short Rituximab Maintenance Improves Progression-Free Survival in Patients with Low-Tumor Burden Follicular Lymphoma. Final Results of FLIRT Phase III Trial, a LYSA Study.

Guillaume Cartron

[Abstract](#)

### ORAL PRESENTATION - EHA 2022

CAR T-Cells Associated Acute Toxicity in B-Cell Non-Hodgkin Lymphoma: Real-World Study from the DESCAR-T Registry

Pierre Sesques

[Abstract](#)

### POSTER PRESENTATION - EHA 2022

A Large French Real World Multicentric Prospective Cohort of Patients with Lymphoma (REALYSA Study): Description of the Diffuse Large B Cell Lymphoma Patients in Real World in France

Hervé Ghesquières

[Abstract](#)

### ORAL PRESENTATION – EHA 2022

A Matched Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Real-Life LYSA Study from The French DESCAR-T Registry

Emmanuel Bachy

[Abstract](#)

### POSTER PRESENTATION - EHA 2022

Intrathecal Methotrexate Prophylaxis and Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with Intensified R-ACVBP Strategy

Loic Renaud

## [Abstract](#)

### **POSTER PRESENTATION - EHA 2022**

Sub-cutaneous Rituximab induction followed by short Rituximab maintenance improves PFS in patients with low-tumor burden follicular lymphoma. Final results of FLIRT phase III trial, a LYSA study.

Guillaume Cartron

[Abstract](#)

## **IFM : Intergroupe Francophone du Myélome**

*Intergroup Francophone of myeloma*

### **ORAL ABSTRACT SESSION – ASCO 2022**

Ixazomib and daratumumab without dexamethasone (i-dara) in elderly frail relapsing myeloma (rrmm) patients: results of the phase 2 study IFM 2018-02 of the Intergroupe Francophone du Myelome (IFM).

Xavier Leleu

[Abstract](#)

### **ORAL ABSTRACT SESSION – ASCO 2022**

Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: Results of the phase 2 study IFM 2018-04

Cyrille Touzeau

[Abstract](#)

### **POSTER PRESENTATION - EHA 2022**

Ixazomib, pomalidomide and dexamethasone (IXPD) in relapsed or refractory multiple myeloma (RRMM) characterized with high-risk cytogenetics. IFM 2014-01

Arthur Bobin

[Abstract](#)

### **POSTER PRESENTATION - EHA 2022**

Ixazomib and daratumumab without dexamethasone (I-DARA) in elderly frail relapsing myeloma (RRMM) patients: results of the phase 2 study ifm 2018-02 of the Intergroupe Francophone du Myelome (IFM).

Margaret Macro

[Abstract](#)

### **POSTER PRESENTATION - EHA 2022**

Carfilzomib in relapsed/refractory multiple myeloma patients: the real-life experience of emmy

C Hulin

[Abstract](#)

### **POSTER PRESENTATION - EHA 2022**

EMMY cohort: management of newly diagnosed or relapsed/ refractory multiple myeloma in patients aged of 80 years and over

Margaret Macro

[Abstract](#)

#### ORAL PRESENTATION - EHA 2022

Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04

Cyrille Touzeau

[Abstract](#)

- 
- More information on the GCO network : [www.gco-cancer.org](http://www.gco-cancer.org)
  - More information on [ASCO](#) and [EHA](#)

